Greg Deters, MD
Family Medicine · Mattoon, ILNPI 1497861702
Payments from drug & device makers
Across 527 payments — averaging $13.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$972
- GSK$823
- Lilly USA, LLC$799
- Novartis$601
- Boehringer Ingelheim$390
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,232100%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 106 | $1,069 |
| AstraZeneca | 60 | $972 |
| GSK | 66 | $823 |
| Lilly USA, LLC | 61 | $799 |
| Novartis | 33 | $601 |
| Boehringer Ingelheim | 26 | $390 |
| Johnson & Johnson | 16 | $252 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $216 |
| Amgen(2 entities) | 15 | $210 |
| Sanofi-aventis U.S. LLC | 15 | $199 |
| AbbVie(2 entities) | 13 | $167 |
| Dexcom, Inc. | 10 | $162 |
| Mylan Specialty L.p. | 11 | $156 |
| Abbott | 9 | $149 |
| Merck | 10 | $146 |
| Pfizer | 10 | $142 |
| Esperion Therapeutics, Inc. | 7 | $109 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| Astellas Pharma US Inc | 5 | $66 |
| Bayer | 4 | $66 |
| Amarin Pharma, Inc. | 5 | $63 |
| Exact Sciences | 3 | $59 |
| E.r. Squibb & Sons, L.L.C. | 4 | $54 |
| Xeris Pharmaceuticals, Inc. | 3 | $47 |
| Supernus Pharmaceuticals, Inc. | 2 | $41 |
| Ultragenyx Pharmaceutical Inc. | 2 | $41 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| Daiichi Sankyo Inc. | 2 | $29 |
| Boston Scientific | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Radius Health, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $11 |
| Eisai Inc. | 1 | $11 |
How this compares
$7,259 in reported general payments places this provider in the 90th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 537 | $204,271 |
| TrulicityDulaglutide | 137 | $148,812 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 177 | $128,635 |
| OzempicSemaglutide | 98 | $117,199 |
| FarxigaDapagliflozin Propanediol | 122 | $79,235 |
| XareltoRivaroxaban | 130 | $74,915 |
| MounjaroTirzepatide | 58 | $73,719 |
| JardianceEmpagliflozin | 84 | $72,922 |
| EntrestoSacubitril/Valsartan | 114 | $62,573 |
| NuedextaDextromethorphan Hbr/Quinidine | 56 | $38,437 |
| RexultiBrexpiprazole | 45 | $28,769 |
| JanuviaSitagliptin Phosphate | 57 | $28,487 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $22,433 |
| LinzessLinaclotide | 35 | $21,302 |
| MyrbetriqMirabegron | 57 | $19,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $799 | $222,531195 claims |
| PfizerEliquis | $142 | $204,271537 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $823 | $159,894247 claims |
| Novo NordiskOzempic, Rybelsus | $1,069 | $129,309110 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $972 | $86,771134 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $390 | $83,42598 claims |
| Johnson & JohnsonXarelto | $252 | $74,915130 claims |
| NovartisEntresto | $601 | $62,573114 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $12 | $38,43756 claims |
| MerckJanuvia, Dulera | $146 | $35,50577 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $66 | $28,76945 claims |
| AbbVieLinzess | $167 | $21,30235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Mattoon
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.